New once-daily 'Quad' pill for HIV is safe, effective alternative to traditional antiretroviral regimens
A new once-daily pill combining three antiretrovirals and a booster molecule is a safe and effective alternative to two widely used drug regimens for newly diagnosed HIV-positive adults who have had no previous treatment. The findings of two large international randomized trials published in this week's Lancet also indicate that the new "Quad" pill is faster acting, doesn't have the neuropsychiatric side effects associated with other combinations, and could improve compliance with treatment.
"Patient adherence to medication is vital, especially for patients with HIV, where missed doses can quickly lead to the virus becoming resistant to medication. Older HIV treatment regimens involve taking several pills multiple times a day", explains Paul Sax from Brigham and Women's Hospital, Harvard Medical School, lead author of the first study. "Our results provide an additional highly potent, well-tolerated treatment option, and highlight the simplicity of treatment resulting from combining several antiretrovirals in a single pill. Studies have shown that single pill treatments improve both adherence and patient satisfaction, and help prevent prescription errors, thereby reducing the likelihood of treatment failure and drug resistance."
Guidelines from the US Department of Health and Human Services currently recommend emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) in combination with a third agentefavirenz (EFV), one of the ritonavir-boosted (RTV) protease inhibitors darunavir or atazanavir (ATV), or the integrase inhibitor raltegraviras the preferred regimen for adults beginning antiretroviral treatment.
The first trial randomly assigned 700 patients from centres across North America to start treatment with two different single tablet regimenseither Quad, combining the new integrase inhibitor elvitegravir (EVG) boosted with cobicistat (a new pharmacoenhancer; COBI) plus FTC/TDF, or a gold standard regimen approved by the FDA in 2006, combining EFV/FTC/TDF (also known as Atripla).
After 48 weeks of treatment, 88% of patients given Quad suppressed viral loads to undetectable levels (less than 50 copies per mL of blood), compared with 84% in the EFV/FTC/TDF group.
Adverse events that led to patients discontinuing treatment were infrequent and similar in both groups. Mild nausea was more common with Quad, but patients were less likely to have dizziness, abnormal dreams, insomnia, and rash compared with the EFV/FTC/TDF regimen.
The second trial included 708 treatment-naïve adults from 146 medical centres across Australia, Europe, North America, and Thailand. Patients were randomly assigned to receive once-daily Quad or a popular and recommended twice-daily combination of ritonavir-boosted atazanavir (ATV/RTV) plus FTC/TDF.
The primary endpoint, to achieve viral levels below 50 copies per mL of blood by week 48, was reached by 90% of people in the Quad group compared with 87% in the ATV/RTV/FTC/TDF group.
The safety of the two regimens was also similar with only 3.7% of patients stopping treatment in the Quad group and 5.1% of patients in the ATV/RTV/FTC/TDF group. However, a higher number of kidney complications were reported in patients taking Quad compared with the other HIV treatments.
"If approved by regulatory agencies, the Quad would be the first once-daily single-tablet regimen containing an HIV integrase inhibitor. Based on the safety and efficacy results from the two large-scale clinical studies, Gilead believes the Quad represents a potentially important new treatment option for a wide range of HIV patients initiating therapy", concludes Brian Kearney, one of the authors from Gilead Sciences who developed the Quad pill.
In a linked Comment, Rik Schrijvers and Zeger Debyser from the Katholieke Universiteit Leuven in Belgium say: "[The studies] show that Quad has high efficacy and a good tolerability profile, with the limitations of potential drug interactions and a need to be taken with food. The underrepresentation of women in these studies, and absence of long-term safety data (especially for renal toxic effects) and resistance data, warrant further research."
Provided by Lancet
- Pivotal study in Africa finds that HIV medications prevent HIV infection Jul 13, 2011 | not rated yet | 0
- HIV integrase inhibitor effective for patients beginning antiretroviral treatment Aug 03, 2009 | not rated yet | 0
- Drug to treat HIV in children shows promise via national study Jan 09, 2012 | not rated yet | 0
- US approves new HIV drug May 21, 2011 | not rated yet | 0
- Nevirapine use may be beneficial for some HIV-infected children who have achieved viral suppression Sep 07, 2010 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Classical and Quantum Mechanics via Lie algebras
Apr 15, 2011 I'd like to open a discussion thread for version 2 of the draft of my book ''Classical and Quantum Mechanics via Lie algebras'', available online at http://lanl.arxiv.org/abs/0810.1019 , and for the...
- More from Physics Forums - Independent Research
More news stories
The integration of mental health interventions into HIV prevention and treatment platforms can reduce the opportunity costs of care and improve treatment outcomes, argues a new Policy Forum article published in this week's ...
HIV & AIDS 17 hours ago | not rated yet | 0
(AP)—The decade-old law that transformed the battle against HIV and AIDS in developing countries is at a crossroads. The dream of future generations freed from the epidemic is running up against an era ...
HIV & AIDS May 21, 2013 | not rated yet | 0
The hunt for an HIV vaccine has gobbled up $8 billion in the past decade, and the failure of the most recent efficacy trial has delivered yet another setback to 26 years of efforts.
HIV & AIDS May 19, 2013 | 5 / 5 (1) | 0
Big names in medicine are set to give an upbeat assessment of the war on AIDS on Tuesday, 30 years after French researchers identified the virus that causes the disease.
HIV & AIDS May 18, 2013 | 5 / 5 (2) | 0
Researchers at the University of Cincinnati (UC) have found that incorporating a peer-referral program for HIV testing into emergency departments can reach new groups of high-risk patients and brings more patients into the ...
HIV & AIDS May 17, 2013 | not rated yet | 0
Research presented today shows that high-fructose corn syrup can cause behavioural reactions in rats similar to those produced by drugs of abuse such as cocaine. These results, presented by addiction expert Francesco Leri, ...
49 minutes ago | 4 / 5 (1) | 0
On May 22, JoVE will publish details of a technique to measure the health of human genetic material in relation to a patient's age. The method is demonstrated by the laboratory of Dr. Gil Atzmon at New York's Albert Einste ...
48 minutes ago | not rated yet | 0
New research shows that craving drugs such as nicotine can be visualized in specific regions of the brain that are implicated in determining the value of actions, in planning actions and in motivation. Dr. Alain Dagher, from ...
47 minutes ago | not rated yet | 0
(Medical Xpress)—Scientists supported by the National Institutes of Health have a new theory as to why a woman's fertility declines after her mid-30s. They also suggest an approach that might help slow ...
2 hours ago | not rated yet | 0 |
Is it permissible to harm one to save many? Those who tend to say "yes" when faced with this classic dilemma are likely to be deficient in a specific kind of empathy, according to a report published in the scientific journal ...
5 hours ago | not rated yet | 0 |
(Medical Xpress)—Health care spending is much higher for older Americans than for younger adults and children, on average, and analysts have said that increasing spending leads to longer life expectancy.
1 hour ago | not rated yet | 0